

Edited by Nathan Brown

 WILEY-VCH

# Bioisosteres in Medicinal Chemistry



**Volume 54**

Series Editors:  
R. Mannhold,  
H. Kubinyi,  
G. Folkers





*Edited by*  
*Nathan Brown*

**Bioisosteres in Medicinal  
Chemistry**

## ***Methods and Principles in Medicinal Chemistry***

Edited by R. Mannhold, H. Kubinyi, G. Folkers

Editorial Board

H. Buschmann, H. Timmerman, H. van de Waterbeemd, T. Wieland

### ***Previous Volumes of this Series:***

Gohlke, Holger (Ed.)

#### **Protein-Ligand Interactions**

2012

ISBN: 978-3-527-32966-3

Vol. 53

Kappe, C. Oliver / Stadler, Alexander / Dallinger, Doris

#### **Microwaves in Organic and Medicinal Chemistry Second, Completely Revised and Enlarged Edition**

2012

ISBN: 978-3-527-33185-7

Vol. 52

Smith, Dennis A. / Allerton, Charlotte /  
Kalgutkar, Amit S. / van de Waterbeemd,  
Han / Walker, Don K.

#### **Pharmacokinetics and Metabolism in Drug Design**

##### **Third, Revised and Updated Edition**

2012

ISBN: 978-3-527-32954-0

Vol. 51

De Clercq, Erik (Ed.)

#### **Antiviral Drug Strategies**

2011

ISBN: 978-3-527-32696-9

Vol. 50

Klebl, Bert / Müller, Gerhard / Hamacher,  
Michael (Eds.)

#### **Protein Kinases as Drug Targets**

2011

ISBN: 978-3-527-31790-5

Vol. 49

Sotriffer, Christoph (Ed.)

#### **Virtual Screening**

##### **Principles, Challenges, and Practical Guidelines**

2011

ISBN: 978-3-527-32636-5

Vol. 48

Rautio, Jarkko (Ed.)

#### **Prodrugs and Targeted Delivery Towards Better ADME Properties**

2011

ISBN: 978-3-527-32603-7

Vol. 47

Smit, Martine J. / Lira, Sergio A. /  
Leurs, Rob (Eds.)

#### **Chemokine Receptors as Drug Targets**

2011

ISBN: 978-3-527-32118-6

Vol. 46

Ghosh, Arun K. (Ed.)

#### **Aspartic Acid Proteases as Therapeutic Targets**

2010

ISBN: 978-3-527-31811-7

Vol. 45

Ecker, Gerhard F. / Chiba, Peter (Eds.)

#### **Transporters as Drug Carriers**

##### **Structure, Function, Substrates**

2009

ISBN: 978-3-527-31661-8

Vol. 44

*Edited by Nathan Brown*

## **Bioisosteres in Medicinal Chemistry**



WILEY-VCH Verlag GmbH & Co. KGaA

#### Series Editors

**Prof. Dr. Raimund Mannhold**

Molecular Drug Research Group  
Heinrich-Heine-Universität  
Universitätsstrasse 1  
40225 Düsseldorf  
Germany  
mannhold@uni-duesseldorf.de

**Prof. Dr. Hugo Kubinyi**

Donnersbergstrasse 9  
67256 Weisenheim am Sand  
Germany  
kubinyi@t-online.de

**Prof. Dr. Gerd Folkers**

Collegium Helveticum  
STW/ETH Zurich  
8092 Zurich  
Switzerland  
folkers@collegium.ethz.ch

#### Volume Editor

**Dr. Nathan Brown**

The Institute of Cancer Research  
Cancer Research UK Cancer  
Therapeutics Unit  
15 Cotswold Road  
Sutton SM2 5NG  
United Kingdom

All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

**Bibliographic information published by  
the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2012 Wiley-VCH Verlag & Co. KGaA,  
Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Composition** Thomson Digital, Noida, India

**Printing and Binding** Markono Print Media Pte Ltd,  
Singapore

**Cover Design** Schulz Grafik-Design, Fußgönheim

**Print ISBN:** 978-3-527-33015-7

**ePDF ISBN:** 978-3-527-65433-8

**ePub ISBN:** 978-3-527-65432-1

**mobi ISBN:** 978-3-527-65431-4

**oBook ISBN:** 978-3-527-65430-7

Printed in Singapore

Printed on acid-free paper

## Contents

**List of Contributors** *XI*

**Preface** *XV*

**A Personal Foreword** *XVII*

### **Part One Principles** 1

#### **1 Bioisosterism in Medicinal Chemistry** 3

*Nathan Brown*

1.1 Introduction 3

1.2 Isosterism 3

1.3 Bioisosterism 6

1.4 Bioisosterism in Lead Optimization 9

1.4.1 Common Replacements in Medicinal Chemistry 9

1.4.2 Structure-Based Drug Design 9

1.4.3 Multiobjective Optimization 12

1.5 Conclusions 13

References 14

#### **2 Classical Bioisosteres** 15

*Caterina Barillari and Nathan Brown*

2.1 Introduction 15

2.2 Historical Background 15

2.3 Classical Bioisosteres 17

2.3.1 Monovalent Atoms and Groups 17

2.3.2 Bivalent Atoms and Groups 17

2.3.3 Trivalent Atoms and Groups 18

2.3.4 Tetravalent Atoms 19

2.3.5 Ring Equivalents 19

2.4 Nonclassical Bioisosteres 20

2.4.1 Carbonyl Group 20

2.4.2 Carboxylic Acid 21

2.4.3 Hydroxyl Group 22

2.4.4 Catechol 22

2.4.5	Halogens	23
2.4.6	Amide and Esters	24
2.4.7	Thiourea	25
2.4.8	Pyridine	26
2.4.9	Cyclic Versus Noncyclic Systems	27
2.5	Summary	27
	References	27
<b>3</b>	<b>Consequences of Bioisosteric Replacement</b>	<b>31</b>
	<i>Dennis A. Smith and David S. Millan</i>	
3.1	Introduction	31
3.2	Bioisosteric Groupings to Improve Permeability	32
3.3	Bioisosteric Groupings to Lower Intrinsic Clearance	40
3.4	Bioisosteric Groupings to Improve Target Potency	43
3.5	Conclusions and Future Perspectives	47
	References	49
<b>Part Two</b>	<b>Data</b>	<b>53</b>
<b>4</b>	<b>BIOSTER: A Database of Bioisosteres and Bioanalogues</b>	<b>55</b>
	<i>István Ujváry and Julian Hayward</i>	
4.1	Introduction	55
4.2	Historical Overview and the Development of BIOSTER	56
4.2.1	Representation of Chemical Transformations for Reaction Databases	56
4.2.2	The Concept of “Biosteric Transformation”	57
4.2.3	Other Analogue and Bioisostere Databases	58
4.3	Description of BIOSTER Database	59
4.3.1	Coverage and Selection Criteria	59
4.3.2	Sources	59
4.3.3	Description of the Layout of Database Records	60
4.3.3.1	ID Code	60
4.3.3.2	Biosteric Transformation	60
4.3.3.3	Citation(s)	62
4.3.3.4	Activity	63
4.3.3.5	Fragments	63
4.3.3.6	Component Molecules and Fragments	64
4.4	Examples	64
4.4.1	Benzodioxole Bioisosteres	65
4.4.2	Phenol Bioisosteres	66
4.4.3	Ketoamides	66
4.5	Applications	69
4.6	Summary	70
4.7	Appendix	70
	References	71

## 5 Mining the Cambridge Structural Database for Bioisosteres 75

*Colin R. Groom, Tjelvar S. G. Olsson, John W. Liebeschuetz,  
David A. Bardwell, Ian J. Bruno, and Frank H. Allen*

- 5.1 Introduction 75
- 5.2 The Cambridge Structural Database 76
- 5.3 The Cambridge Structural Database System 78
  - 5.3.1 ConQuest 78
  - 5.3.2 Mercury 78
  - 5.3.3 WebCSD 79
- 5.3.4 Knowledge-Based Libraries Derived from the CSD 80
- 5.4 The Relevance of the CSD to Drug Discovery 83
- 5.5 Assessing Bioisosteres: Conformational Aspects 84
- 5.6 Assessing Bioisosteres: Nonbonded Interactions 86
- 5.7 Finding Bioisosteres in the CSD: Scaffold Hopping and  
Fragment Linking 91
  - 5.7.1 Scaffold Hopping 91
  - 5.7.2 Fragment Linking 92
- 5.8 A Case Study: Bioisosterism of 1*H*-Tetrazole and Carboxylic  
Acid Groups 94
  - 5.8.1 Conformational Mimicry 94
  - 5.8.2 Intermolecular Interactions 94
- 5.9 Conclusions 97
- References 98

## 6 Mining for Context-Sensitive Bioisosteric Replacements in Large Chemical Databases 103

*George Papadatos, Michael J. Bodkin, Valerie J. Gillet,  
and Peter Willett*

- 6.1 Introduction 103
- 6.2 Definitions 104
- 6.3 Background 105
- 6.4 Materials and Methods 109
  - 6.4.1 Human Microsomal Metabolic Stability 109
  - 6.4.2 Data Preprocessing 109
  - 6.4.3 Generation of Matched Molecular Pairs 110
  - 6.4.4 Context Descriptors 111
    - 6.4.4.1 Whole Molecule Descriptors 111
    - 6.4.4.2 Local Environment Descriptors 112
  - 6.4.5 Binning of  $\Delta P$  Values 112
  - 6.4.6 Charts and Statistics 112
- 6.5 Results and Discussion 113
  - 6.5.1 General Considerations 123
- 6.6 Conclusions 124
- References 125

**Part Three Methods 129****7 Physicochemical Properties 131***Peter Ertl*

- 7.1 Introduction 131
- 7.2 Methods to Identify Bioisosteric Analogues 132
- 7.3 Descriptors to Characterize Properties of Substituents and Spacers 132
- 7.4 Classical Methods for Navigation in the Substituent Space 135
- 7.5 Tools to Identify Bioisosteric Groups Based on Similarity in Their Properties 136
- 7.6 Conclusions 138
- References 138

**8 Molecular Topology 141***Nathan Brown*

- 8.1 Introduction 141
- 8.2 Controlled Fuzziness 141
- 8.3 Graph Theory 142
- 8.4 Data Mining 144
  - 8.4.1 Graph Matching 144
  - 8.4.2 Fragmentation Methods 145
- 8.5 Topological Pharmacophores 146
- 8.6 Reduced Graphs 149
- 8.7 Summary 151
- References 152

**9 Molecular Shape 155***Pedro J. Ballester and Nathan Brown*

- 9.1 Methods 156
  - 9.1.1 Superposition-Based Shape Similarity Methods 156
  - 9.1.2 Superposition-Free Shape Similarity Methods 158
  - 9.1.3 Choosing a Shape Similarity Technique for a Particular Project 160
- 9.2 Applications 161
- 9.3 Future Prospects 164
- References 165

**10 Protein Structure 167***James E. J. Mills*

- 10.1 Introduction 167
- 10.2 Database of Ligand–Protein Complexes 168
  - 10.2.1 Extraction of Ligands 168
  - 10.2.2 Assessment of Ligand and Protein Criteria 169

10.2.3	Cavity Generation	170
10.2.4	Generation and Validation of SMILES String	170
10.2.5	Generation of FASTA Sequence Files	171
10.2.6	Identification of Intermolecular Interactions	172
10.3	Generation of Ideas for Bioisosteres	173
10.3.1	Substructure Search	173
10.3.2	Sequence Search	175
10.3.3	Binding Pocket Superposition	175
10.3.4	Bioisostere Identification	176
10.4	Context-Specific Bioisostere Generation	177
10.5	Using Structure to Understand Common Bioisosteric Replacements	178
10.6	Conclusions	180
	References	180
<b>Part Four</b>	<b>Applications</b>	<b>183</b>
<b>11</b>	<b>The Drug Guru Project</b>	<b>185</b>
	<i>Kent D. Stewart, Jason Shanley, Karam B. Alsayyed Ahmed, and J. Phillip Bowen</i>	
11.1	Introduction	185
11.2	Implementation of Drug Guru	187
11.3	Bioisosteres	188
11.4	Application of Drug Guru	194
11.5	Quantitative Assessment of Drug Guru Transformations	195
11.6	Related Work	197
11.7	Summary: The Abbott Experience with the Drug Guru Project	197
	References	198
<b>12</b>	<b>Bioisosteres of an NPY-Y5 Antagonist</b>	<b>199</b>
	<i>Nicholas P. Barton and Benjamin R. Bellenie</i>	
12.1	Introduction	199
12.2	Background	199
12.3	Potential Bioisostere Approaches	201
12.4	Template Molecule Preparation	204
12.5	Database Molecule Preparation	206
12.6	Alignment and Scoring	206
12.7	Results and Monomer Selection	207
12.8	Synthesis and Screening	208
12.9	Discussion	209
12.10	SAR and Developability Optimization	211
12.11	Summary and Conclusion	214
	References	214

<b>13</b>	<b>Perspectives from Medicinal Chemistry</b>	<b>217</b>
	<i>Nicholas A. Meanwell, Marcus Gastreich, Matthias Rarey, Mike Devereux, Paul L.A. Popelier, Gisbert Schneider, and Peter Willett</i>	
13.1	Introduction	217
13.2	Pragmatic Bioisostere Replacement in Medicinal Chemistry: A Software Maker's Viewpoint	219
13.3	The Role of Quantum Chemistry in Bioisostere Prediction	221
13.4	Learn from "Naturally Drug-Like" Compounds	223
13.5	Bioisosterism at the University of Sheffield	224
	References	227
	<b>Index</b>	<b>231</b>

## List of Contributors

### **Frank H. Allen**

Cambridge Crystallographic Data  
Centre (CCDC)  
12 Union Road  
Cambridge CB2 1EZ  
UK

### **Karam B. Alsayyed Ahmed**

University of North Carolina at  
Greensboro  
Department of Chemistry & Biochemistry  
Center for Drug Design  
Greensboro, NC 27410  
USA

### **Pedro J. Ballester**

European Bioinformatics Institute  
Wellcome Trust Genome Campus  
Hinxton, Cambridge CB10 1SD  
UK

### **David A. Bardwell**

Cambridge Crystallographic Data  
Centre (CCDC)  
12 Union Road  
Cambridge CB2 1EZ  
UK

### **Caterina Barillari**

The Institute of Cancer Research  
Cancer Research UK Cancer  
Therapeutics Unit  
15 Cotswold Road  
Sutton SM2 5NG  
UK

### **Nicholas P. Barton**

GlaxoSmithKline Pharmaceuticals  
New Frontiers Science Park (North)  
Coldharbour Road  
Harlow, Essex CM15 5AD  
UK

### **Michael J. Bodkin**

Eli Lilly Limited  
Erl Wood Manor  
Windlesham, Surrey GU20 6PH  
UK

### **J. Phillip Bowen**

University of North Carolina at  
Greensboro  
Department of Chemistry &  
Biochemistry  
Center for Drug Design  
Greensboro, NC 27410  
USA

and

Mercer University  
College of Pharmacy and Health  
Sciences  
Department of Pharmaceutical Sciences  
3001 Mercer University Drive  
Atlanta, GA 30341  
USA

**Nathan Brown**

The Institute of Cancer Research  
Cancer Research UK Cancer  
Therapeutics Unit  
15 Cotswold Road  
Sutton SM2 5NG  
UK

**Ian J. Bruno**

Cambridge Crystallographic Data  
Centre (CCDC)  
12 Union Road  
Cambridge CB2 1EZ  
UK

**Mike Devereux**

University of Basel  
Klingelbergstrasse 80  
4056 Basel  
Switzerland

**Peter Ertl**

Novartis Institutes for BioMedical  
Research  
Novartis Campus  
4056 Basel  
Switzerland

**Marcus Gastreich**

BioSolveIT  
An der Ziegelei 79  
53757 St. Augustin  
Germany

**Valerie J. Gillet**

The University of Sheffield  
Information School  
Regent Court  
211 Portobello  
Sheffield S1 4DP  
UK

**Colin R. Groom**

Cambridge Crystallographic Data  
Centre (CCDC)  
12 Union Road  
Cambridge CB2 1EZ  
UK

**Julian Hayward**

Digital Chemistry Ltd  
30 Kiveton Lane  
Todwick, Sheffield S26 1HL  
UK

**John W. Liebeschuetz**

Cambridge Crystallographic Data  
Centre (CCDC)  
12 Union Road  
Cambridge CB2 1EZ  
UK

**Nicholas A. Meanwell**

Bristol-Myers Squibb Pharmaceutical  
Research and Development  
Department of Medicinal Chemistry  
5 Research Parkway  
Wallingford, CT 06492  
USA

**David Millan**

Sandwich Laboratories  
Pfizer Global Research and  
Development  
Ramsgate Road  
Sandwich, Kent CT13 9NJ  
UK

**James E. J. Mills**

Sandwich Laboratories  
Pfizer Global Research and  
Development  
Ramsgate Road  
Sandwich, Kent CT13 9NJ  
UK

**Tjelvar J. Olsson**

Cambridge Crystallographic Data  
Centre (CCDC)  
12 Union Road  
Cambridge CB2 1EZ  
UK

**George Papadatos**

Eli Lilly Limited  
Erl Wood Manor  
Windlesham, Surrey GU20 6PH  
UK

**Paul L.A. Popelier**

University of Manchester  
Manchester Interdisciplinary Biocentre  
(MIB)  
131 Princess Street  
Manchester M1 7DN  
UK

and

University of Manchester  
School of Chemistry  
Oxford Road  
Manchester M13 9PL  
UK

**Matthias Rarey**

ZBH University of Hamburg  
Bundesstrasse 43  
20146 Hamburg  
Germany

**Gisbert Schneider**

ETH Zurich  
Institute of Pharmaceutical Sciences  
8093 Zurich  
Switzerland

**Jason Shanley**

Abbott Laboratories  
Global Pharmaceutical Research and  
Development  
Department of Structural Biology  
100 Abbott Park Road  
Abbott Park, IL 60031  
USA

**Dennis A. Smith**

Sandwich Laboratories  
Pfizer Global Research and  
Development  
Ramsgate Road  
Sandwich, Kent CT13 9NJ  
UK

**Kent D. Stewart**

Abbott Laboratories  
Global Pharmaceutical Research and  
Development  
Department of Structural Biology  
100 Abbott Park Road  
Abbott Park, IL 60031  
USA

**István Ujváry**

iKem BT  
Búza u. 32  
1033 Budapest  
Hungary

**Peter Willett**

University of Sheffield  
Information School  
Sheffield S1 4DP  
UK



## Preface

Bioisosteric replacement of substituents, ring atoms, linkers, and other groups aims to generate chemical substitutes with related biological properties, in the hope that the new analogues may have somewhat better properties. Such replacements are the toolbox of medicinal chemists to optimize their lead structures with respect to lipophilicity, solubility, activity, selectivity, absorption, metabolism, and lack of toxic and other side effects. Whenever an analogue with some improved properties is observed, the new compound is taken as the starting point for further modification. In this evolutionary procedure, either a preclinical or a clinical candidate results or the project has to be terminated, without success. Whereas the whole process quite often follows a trial and error procedure, certain empirical rules developed in medicinal chemistry. Very simple ones are, for example, the replacement of a hydrogen atom in the *para*-position of a benzene ring, to avoid rapid metabolic degradation, or, on the other hand, the introduction of an aromatic methyl group instead of a chlorine atom, to avoid too long biological half-life. More sophisticated rules exist for modification of the ligands of certain targets, for example, proteases or kinases.

The organization of this book follows a logical sequence, starting with Part One on the principles of bioisosterism, including an introductory chapter, and chapters on classical bioisosteres in medicinal chemistry and the logical but often surprising consequences of bioisosteric replacement. Part Two presents a database on bioisosteres and bioanalogues and discusses the search for bioisosteres, using the Cambridge Structure Database of 3D structures of small molecules, as well as the mining of bioisosteric pairs. Part Three presents methods to identify bioisosteres under the aspect of physicochemical properties, molecular topology, molecular shape, and protein 3D structures. Part Four describes a computer program for drug design, using medicinal chemistry rules, discusses the bioisosteric modification of a receptor antagonist, and ends with a concluding chapter on perspectives from medicinal chemistry.

Whereas some reviews on bioisosteres are found in the literature, as well as chapters in medicinal chemistry books, no dedicated monograph on bioisosteres has been published so far. Thus, we are very grateful to Nathan Brown for editing such a book, which will help novices in the field as well as experienced scientists to manage lead structure optimization in an even more rational manner. In addition, we are

very much indebted to Frank Weinreich and Heike Nöthe, both at Wiley-VCH. Their support and ongoing engagement, not only for this book but also for the whole series “Methods and Principles in Medicinal Chemistry,” adds to the success of this excellent collection of monographs on various topics, all related to drug research.

March 2012  
Düsseldorf  
Weisenheim am Sand  
Zürich

*Raimund Mannhold*  
*Hugo Kubinyi*  
*Gerd Folkers*

## A Personal Foreword

“Hamlet: Do you see yonder cloud that’s almost in shape of a camel?”

Polonius: By th’ Mass, and ’tis like a camel, indeed.

Hamlet: Methinks it is like a weasel.

Polonius: It is backed like a weasel.

Hamlet: Or like a whale.

Polonius: Very like a whale.”

*Hamlet*, Act III, Scene II  
William Shakespeare

The essence of design is the identification of appropriate constituents and their careful arrangement in sympathy with the requirements of the desired object. The same principles apply in drug design, where the components are elements and elemental groups, and their arrangement is achieved through the synthetic organic chemistry that is undertaken. The ultimate requirement in the design of new drugs is an entity that summons a physiological response of benefit to the patient.

In this book, we cover the key aspects of drug design through the identification and replacement of bioisosteric groups within the context of the drug design ethic. Bioisosterism is a phenomenon where molecular groups are functionally similar, that is, they have a similar biological effect, while modulating other properties. This is the first book to provide a general overview of the field of bioisosterism at a time when its application has become a formal process. There are now many information sources and design tools available to assist the medicinal chemist in the identification of relevant bioisosteres.

The first part of this book covers the historical aspects of bioisosterism, from its founding principles of isosterism from Langmuir through defined sets of classical isosteres and bioisosteres, to the potential consequences of bioisosteric replacement in context.

A considerable amount of knowledge has been collated in recent years, in large molecular databases with metadata that can be analyzed and brought to bear in bioisosteric replacement. Knowledge-based methods form the second part, covering experimentally determined bioisosteric replacements from the medicinal chemistry

literature; small-molecule crystal identification of bioisosteres; and mining unknown bioisosteres from these databases through the application of recently developed methods for their identification.

One can describe a molecule in many ways and the same applies to bioisosteres. Molecular descriptor methods are covered in the third part by the application of different representations. A number of computational approaches to bioisosteric replacement are covered in chapters on physicochemical properties, molecular topology, molecular shape, and the use of protein structure information. Each chapter covers many common methods and overviews of when best to apply these methods, and where they have been successfully applied.

This book concludes with two case studies of where bioisosteric replacement strategies have been applied in drug discovery, to provide demonstrable evidence of their utility. Finally, a few leading scientists in this field have kindly provided personal perspectives on bioisosterism and its relevance to drug discovery.

My sincere wish is that you enjoy reading this book as much as I did working with the very talented team of scientists who contributed chapters. I would also like to thank the publishing team and the series editors for their help in bringing this book together.

London, 2012

*Nathan Brown*

## Part one

### Principles



# 1

## Bioisosterism in Medicinal Chemistry

Nathan Brown

### 1.1

#### Introduction

One of the key challenges for the medicinal chemist today is the modulation and mediation of the potency of a small-molecule therapeutic against its biological target. In addition, it is essential to ensure that the molecule reaches its target effectively while also ensuring that it satisfies necessary safety requirements. One of the most significant approaches to assist in efficiently navigating the available chemistry space is that of bioisosteric replacement.

This book, the first dedicated solely to the subject of bioisosterism, covers the field from the very beginning to its development as a reliable and well-used approach to assist in drug design. This book is split into four parts. The first part covers the principles and theory behind isosterism and bioisosterism. The second part investigates methods that apply knowledge bases of experimental data from a variety of sources to assist in decision making. The third part reports on the four main computational approaches to bioisosteric identification and replacement using molecular properties, topology, shape, and protein structure. This book concludes with real-world examples of bioisosterism in application and a collection of reflections and perspectives on bioisosteric identification and replacement from many of the current leaders in the field.

This chapter provides an overview of the history of bioisosterism from its beginning in the early twentieth century to the present day. We also provide an overview of the importance of judicious bioisosteric replacement in lead optimization to assist in the path toward a viable clinical candidate and, ultimately, a drug.

### 1.2

#### Isosterism

James Moir [1] first considered isosterism in all but name, in 1909. It was not until 1919 that the term isosterism was given to this phenomenon by Irving Langmuir [2] in his landmark paper “Isomorphism, isosterism and covalence.” The focus of this

**Table 1.1** Experimental data from Landolt–Börnstein’s tables and Abegg’s handbook for nitrous oxide (N<sub>2</sub>O) and carbon dioxide (CO<sub>2</sub>).

Property	N <sub>2</sub> O	CO <sub>2</sub>
Critical pressure (atm)	75	77
Critical temperature (°C)	35.4	31.9
Viscosity at 20 °C	$148 \times 10^{-6}$	$148 \times 10^{-6}$
Heat conductivity at 100 °C	0.0506	0.0506
Density of liquid at –20 °C	0.996	1.031
Density of liquid at +10 °C	0.856	0.858
Refractive index of liquid, D line, 16 °C	1.193	1.190
Dielectric constant of liquid at 0 °C	1.598	1.582
Magnetic susceptibility of gas at 40 atm, 16 °C	$0.12 \times 10^{-6}$	$0.12 \times 10^{-6}$
Solubility in water at 0 °C	1.305	1.780
Solubility in alcohol at 15 °C	3.25	3.13

early isosterism work was on the electronic configuration of atoms. Langmuir used experiment to identify the correspondence between the physical properties of different substances. Langmuir, in accordance with the octet rule where atoms will often combine to have eight electrons in their valence shells, compared the number and arrangement of electrons between nitrogen, carbon monoxide, and the cyanogen ion and identified that these would be the same. This relationship was demonstrated to be true between nitrogen and carbon monoxide in terms of their physical properties. The same similarities were also reported between nitrous oxide and carbon dioxide when taking experimental data from Landolt–Börnstein’s tables and Abegg’s handbook (Table 1.1).

However, Langmuir identified one distinct property that is substantially different between nitrous oxide and carbon dioxide, the freezing point: –102 and –56 °C, respectively. Evidence for this was assumed to be due to the freezing point being “abnormally sensitive to even slight differences in structure.”

With this observation of the correlation between the structure and arrangement of electrons with physical properties, Langmuir defined the neologism calling them isosteres, or isosteric compounds. Langmuir defined isosterism as follows:

“Comolecules are thus isosteric if they contain the same number and arrangement of electrons. The comolecules of isosteres must, therefore, contain the same number of atoms. The essential differences between isosteres are confined to the charges on the nuclei of the constituent atoms. Thus in carbon dioxide the charges on the nuclei of the carbon and oxygen atoms are 6 and 8, respectively, and there are  $2 \times 8 + 6 = 22$  electrons in the molecule. In nitrous oxide the number of charges on the nitrogen nuclei is 7, but the total number of electrons in the molecule is again  $2 \times 7 + 8 = 22$ . The remarkable similarity of the physical properties of these two substances proves that their electrons are arranged in the same manner.”

**Table 1.2** List of isosteres defined by Langmuir in 1919.

Type	Isosteres
1	$\text{H}^-$ , He, $\text{Li}^+$
2	$\text{O}^{2-}$ , $\text{F}^-$ , Ne, $\text{Na}^+$ , $\text{Mg}^{2+}$ , $\text{Al}^{3+}$
3	$\text{S}^{2-}$ , $\text{Cl}^-$ , Ar, $\text{K}^+$ , $\text{Ca}^{2+}$
4	$\text{Cu}^+$ , $\text{Zn}^{2+}$
5	$\text{Br}^-$ , Kr, $\text{Rb}^+$ , $\text{Sr}^{2+}$
6	$\text{Ag}^+$ , $\text{Cd}^{2+}$
7	$\text{I}^-$ , Xe, $\text{Cs}^+$ , $\text{Ba}^{2+}$
8	$\text{N}_2$ , CO, $\text{CN}^-$
9	$\text{CH}_4$ , $\text{NH}_4^+$
10	$\text{CO}_2$ , $\text{N}_2\text{O}$ , $\text{N}_3^-$ , $\text{CNO}^-$
11	$\text{NO}_3^-$ , $\text{CO}_3^{2-}$
12	$\text{NO}_2^-$ , $\text{O}_3$
13	HF, $\text{OH}^-$
14	$\text{ClO}_4^-$ , $\text{SO}_4^{2-}$ , $\text{PO}_4^{3-}$
15	$\text{ClO}_3^-$ , $\text{SO}_4^{2-}$ , $\text{PO}_4^{3-}$
16	$\text{SO}_3$ , $\text{PO}_3^-$
17	$\text{S}_2\text{O}_6^{2-}$ , $\text{P}_2\text{O}_6^{4-}$
18	$\text{S}_2\text{O}_7^{2-}$ , $\text{P}_2\text{O}_7^{4-}$
19	$\text{SiH}_4$ , $\text{PH}_4^+$
20	$\text{MnO}_4^-$ , $\text{CrO}_4^{2-}$
21	$\text{SeO}_4^{2-}$ , $\text{AsO}_4^{3-}$

The list of isosteres that Langmuir described in 1919 is given in Table 1.2. Langmuir extended his concept of isosterism to predicting likely crystal forms using sodium and fluorine ions as exemplars, these having been solved by William Henry Bragg and William Lawrence Bragg – father and son who were together awarded the Nobel Prize for Physics in 1915. Since the magnesium and oxygen ions are isosteric with the sodium and fluorine ions, it follows that magnesium oxide will have a crystal structure that is identical to that of sodium fluoride.

In 1925, H.G. Grimm [3] extended the concept of isosterism, introduced by Langmuir, with Grimm's hydride displacement law:

“Atoms anywhere up to four places in the periodic system before an inert gas change their properties by uniting with one to four hydrogen atoms, in such a manner that the resulting combinations behave like pseudoatoms, which are similar to elements in the groups one to four places, respectively, to their right.”

Therefore, according to this law, the addition of hydrogen to an atom will result in a *pseudoatom* with similar properties to the atom of the next highest atomic number. So, CH is isosteric with N and NH is isosteric with O and so on.

Beginning in 1932, Friedrich Erlenmeyer [4, 5] extended the concepts from Grimm further and the first applications of isosterism to biological systems. Erlenmeyer redefined isosteres as:

“...elements, molecules or ions in which the peripheral layers of electrons may be considered identical.”

In addition, Erlenmeyer also proposed the following three additions to the concept of isosteres:

- 1) All elements within the same group in the periodic table are isosteres of each other. Therefore, silicon and carbon are isosteres of each other, as are oxygen and sulfur.
- 2) Pseudoatoms are included to characterize groups that appear superficially different but are actually very similar in physical properties. Pseudohalogens are an instance of this class, where  $\text{Cl} \approx \text{CN} \approx \text{SCN}$ , and so on.
- 3) Finally, ring equivalences are included to permit isosteric matches between different ring systems. One example is the isosteric properties between benzene and thiophene, where  $-\text{CH}=\text{CH}- \approx -\text{S}-$ .

It was with Erlenmeyer that the concept of bioisosterism was introduced to differentiate from classical isosteres, ensuring its relevance to medicinal chemistry. The introduction of ring equivalences is significant. This was the formalization of what we consider to be a bioisosteric comparison and is the first definition of most relevance to medicinal chemistry.

### 1.3

#### Bioisosterism

Classical isosteres are traditionally categorized into the following distinct groupings [6]:

- 1) Monovalent atoms or groups.
- 2) Divalent atoms or groups.
- 3) Trivalent atoms or groups.
- 4) Tetrasubstituted atoms.
- 5) Ring equivalents.

A number of classical bioisosteric examples are provided in Table 1.3 that illustrate typical replacements possible in each of these five groups.

However, more recent definitions of isosterism, and more specifically bioisosterism, relax these constraints and permit bioisosteric pairings between moieties that do not necessarily contain the same number of atoms. Specifically, nonclassical bioisosteres include the addition of the following two groups:

- 1) Rings versus acyclic structures.
- 2) Exchangeable groups.